The latest Investing Matters Podcast episode featuring financial educator and author Jared Dillian has been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksREDX.L Regulatory News (REDX)

  • There is currently no data for REDX

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

TR-1: Notification of major holdings

8 Nov 2023 13:58

RNS Number : 8260S
Redx Pharma plc
08 November 2023
 

TR-1: Standard form for notification of major holdings

 

NOTIFICATION OF MAJOR HOLDINGS (to be sent to the relevant issuer and to the FCA in Microsoft Word format if possible)i

1a. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attachedii:

Redx Pharma PLC

1b. Please indicate if the issuer is a non-UK issuer (please mark with an "X" if appropriate)

Non-UK issuer

2. Reason for the notification (please mark the appropriate box or boxes with an "X")

An acquisition or disposal of voting rights

X

An acquisition or disposal of financial instruments

An event changing the breakdown of voting rights

Other (please specify)iii: increase in total voting rights of issuer

X

3. Details of person subject to the notification obligationiv

Name

Redmile Group, LLC

City and country of registered office (if applicable)

San Francisco, USA

4. Full name of shareholder(s) (if different from 3.)v

Name

RM Special Holdings 3, LLC

RedCo II Master Fund, L.P.

City and country of registered office (if applicable)

San Francisco, USA

5. Date on which the threshold was crossed or reachedvi:

07/11/2023

6. Date on which issuer notified (DD/MM/YYYY):

08/11/2023

7. Total positions of person(s) subject to the notification obligation

% of voting rights attached to shares (total of 8. A)

% of voting rights through financial instruments(total of 8.B 1 + 8.B 2)

Total of both in % (8.A + 8.B)

Total number of voting rights of issuervii

Resulting situation on the date on which threshold was crossed or reached

71.18

N/A

71.18

276,890,319

Position of previous notification (if

applicable)

73.60

N/A

73.60

245,341,627

 

8. Notified details of the resulting situation on the date on which the threshold was crossed or reachedviii

A: Voting rights attached to shares

Class/type ofshares

ISIN code (if possible)

Number of voting rightsix

% of voting rights

Direct

(Art 9 of Directive 2004/109/EC) (DTR5.1)

Indirect

(Art 10 of Directive 2004/109/EC) (DTR5.2.1)

Direct

(Art 9 of Directive 2004/109/EC) (DTR5.1)

Indirect

(Art 10 of Directive 2004/109/EC) (DTR5.2.1)

Ordinary Shares

GB00BSNB6S51

N/A

276,890,319

N/A

276,890,319

SUBTOTAL 8. A

276,890,319

71.18

 

 

B 1: Financial Instruments according to Art. 13(1)(a) of Directive 2004/109/EC (DTR5.3.1.1 (a))

Type of financial instrument

Expirationdatex

Exercise/Conversion Periodxi

Number of voting rights that may be acquired if the instrument is

exercised/converted.

% of voting rights

SUBTOTAL 8. B 1

 

 

B 2: Financial Instruments with similar economic effect according to Art. 13(1)(b) of Directive 2004/109/EC (DTR5.3.1.1 (b))

Type of financial instrument

Expirationdatex

Exercise/Conversion Period xi

Physical or cash

settlementxii

Number of voting rights

% of voting rights

 

SUBTOTAL 8.B.2

 

 

 

 

9. Information in relation to the person subject to the notification obligation (please mark the

applicable box with an "X")

Person subject to the notification obligation is not controlled by any natural person or legal entity and does not control any other undertaking(s) holding directly or indirectly an interest in the (underlying) issuerxiii

Full chain of controlled undertakings through which the voting rights and/or thefinancial instruments are effectively held starting with the ultimate controlling natural person or legal entityxiv (please add additional rows as necessary)

X

Namexv

% of voting rights if it equals or is higher than the notifiable threshold

% of voting rights through financial instruments if it equals or is higher than the notifiable threshold

Total of both if it equals or is higher than the notifiable threshold

Redmile Group, LLC

RM Special Holdings 3, LLC

56.01

N/A

56.01

Redmile Group, LLC

RedCo II Master Fund, L.P.

15.17

N/A

15.17

 

10. In case of proxy voting, please identify:

Name of the proxy holder

The number and % of voting rights held

The date until which the voting rights will be held

11. Additional informationxvi

Redmile Group, LLC manages the investments of RM Special Holdings 3, LLC and RedCo II Master Fund, L.P.

 

Place of completion

San Francisco, USA

Date of completion

07/11/2023

 

 

Notes

 

i Please note that national forms may vary due to specific national legislation (Article 3(1a) of Directive 2004/109/EC) as for instance the applicable thresholds or information regarding capital holdings.

 

ii Full name of the legal entity and further specification of the issuer or underlying issuer, provided it is reliable and accurate (e.g. address, LEI, domestic number identity). Indicate in the relevant section whether the issuer is a non UK issuer.

 

iii Other reason for the notification could be voluntary notifications, changes of attribution of the nature of the holding (e.g. expiring of financial instruments) or acting in concert.

 

iv This should be the full name of (a) the shareholder; (b) the natural person or legal entity acquiring, disposing of or exercising voting rights in the cases provided for in DTR5.2.1 (b) to (h)/ Article 10 (b) to (h) of Directive 2004/109/EC; (c) all parties to the agreement referred to in Article 10 (a) of Directive 2004/109/EC (DTR5.2.1 (a)) or (d) the holder of financial instruments referred to in Article 13(1) of Directive 2004/109/EC (DTR5.3.1).

 

As the disclosure of cases of acting in concert may vary due to the specific circumstances (e.g. same or different total positions of the parties, entering or exiting of acting in concert by a single party) the standard form does not provide for a specific method how to notify cases of acting in concert.

 

In relation to the transactions referred to in points (b) to (h) of Article 10 of Directive 2004/109/EC (DTR5.2.1 (b) to (h)), the following list is provided as indication of the persons who should be mentioned:

 

- in the circumstances foreseen in letter (b) of Article 10 of that Directive (DTR5.2.1 (b)), the natural person or legal entity that acquires the voting rights and is entitled to exercise them under the agreement and the natural person or legal entity who is transferring temporarily for consideration the voting rights;

 

- in the circumstances foreseen in letter (c) of Article 10 of that Directive (DTR5.2.1 (c)), the natural person or legal entity holding the collateral, provided the person or entity controls the voting rights and declares its intention of exercising them, and natural person or legal entity lodging the collateral under these conditions;

 

- in the circumstances foreseen in letter (d) of Article 10 of that Directive (DTR5.2.1 (d)), the natural person or legal entity who has a life interest in shares if that person or entity is entitled to exercise the voting rights attached to the shares and the natural person or legal entity who is disposing of the voting rights when the life interest is created;

 

- in the circumstances foreseen in letter (e) of Article 10 of that Directive (DTR5.2.1 (e)), the controlling natural person or legal entity and, provided it has a notification duty at an individual level under Article 9 (DTR 5.1), under letters (a) to (d) of Article 10 of that Directive (DTR5.2.1 (a) to (d)) or under a combination of any of those situations, the controlled undertaking;

 

- in the circumstances foreseen in letter (f) of Article 10 of that Directive (DTR5.2.1 (f)), the deposit taker of the shares, if he can exercise the voting rights attached to the shares deposited with him at his discretion, and the depositor of the shares allowing the deposit taker to exercise the voting rights at his discretion;

 

- in the circumstances foreseen in letter (g) of Article 10 of that Directive (DTR5.2.1 (g)), the natural person or legal entity that controls the voting rights;

 

- in the circumstances foreseen in letter (h) of Article 10 of that Directive (DTR5.2.1 (h)), the proxy holder, if he can exercise the voting rights at his discretion, and the shareholder who has given his proxy to the proxy holder allowing the latter to exercise the voting rights at his discretion (e.g. management companies).

 

v Applicable in the cases provided for in Article 10 (b) to (h) of Directive 2004/109/EC (DTR5.2.1 (b) to (h). This should be the full name of the shareholder who is the counterparty to the natural person or legal entity referred to in Article 10 of that Directive (DTR5.2) unless the percentage of voting rights held by the shareholder is lower than the lowest notifiable threshold for the disclosure of voting rights holdings in accordance with national practices (e.g. identification of funds managed by management companies).

 

vi The date on which threshold is crossed or reached should be the date on which the acquisition or disposal took place or the other reason triggered the notification obligation. For passive crossings, the date when the corporate event took effect.

 

vii The total number of voting rights shall be composed of all the shares, including depository receipts representing shares, to which voting rights are attached even if the exercise thereof is suspended.

 

viii If the holding has fallen below the lowest applicable threshold in accordance with national law, please note that it might not be necessary in accordance with national law to disclose the extent of the holding, only that the new holding is below that threshold.

 

ix In case of combined holdings of shares with voting rights attached "direct holding" and voting rights "indirect holding", please split the voting rights number and percentage into the direct and indirect columns - if there is no combined holdings, please leave the relevant box blank.

 

x Date of maturity/expiration of the financial instrument i.e. the date when right to acquire shares ends.

 

xi If the financial instrument has such a period - please specify this period - for example once every 3 months starting from [date].

 

xii In case of cash settled instruments the number and percentages of voting rights is to be presented on a delta-adjusted basis (Article 13(1a) of Directive 2004/109/EC) (DTR 5.3.3.A).

 

xiii If the person subject to the notification obligation is either controlled and/or does control another undertaking then the second option applies.

 

xiv The full chain of controlled undertakings starting with the ultimate controlling natural person or legal entity has to be presented also in the cases, in which only on subsidiary level a threshold is crossed or reached and the subsidiary undertaking discloses the notification as only thus the markets get always the full picture of the group holdings. In case of multiple chains through which the voting rights and/or financial instruments are effectively held the chains have to be presented chain by chain leaving a row free between different chains (e.g.: A, B, C, free row, A, B, D, free row, A, E, F etc.).

 

xv The names of controlled undertakings through which the voting rights and/or financial instruments are effectively held have to be presented irrespectively whether the controlled undertakings cross or reach the lowest applicable threshold themselves.

 

xvi Example: Correction of a previous notification.

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
HOLUWVOROVUARAA
Date   Source Headline
3rd Jan 20197:00 amRNSRedx to present at 2019 Biotech Showcase event
28th Dec 201811:47 amRNSPublication of Annual Report and Accounts
30th Nov 20188:45 amEQSHardman & Co Research: RedX Pharma (REDX): RXC006: First fibrosis development candidate
30th Nov 20187:00 amRNSFirst RXC006 data for treatment of fibrosis
27th Nov 20184:05 pmEQSHardman & Co Research: Redx Pharma (REDX): Streamlined, focused and good value
19th Nov 20187:00 amRNSCFO Announcement
19th Nov 20187:00 amRNSPreliminary Results for year ended 30 Sept 2018
14th Nov 20187:00 amRNSRedx announces new drug development candidate
9th Nov 20189:51 amEQSHardman & Co Research: Redx Pharma (REDX):ROCK2 inhibitors in chronic kidney disease
5th Nov 20187:00 amRNSPreclinical data presented at cancer conference
31st Oct 20187:00 amRNSNotice of Results
29th Oct 20187:00 amRNSRedx notes election of Lisa Anson to UK BIA BOD
26th Oct 20187:00 amRNSDetails from Redx ROCK2 inhibitor poster
22nd Oct 20187:00 amRNSRedx ROCK2 inhibitors poster to be presented
2nd Oct 20181:40 pmEQSHardman & Co Research: Redx Pharma (REX): Strategy launch
6th Sep 20187:15 amEQSHardman & Co Research: Redx Pharma (REDX): Back to the clinic
4th Sep 20187:00 amRNSRedx Pharma Announces Way Forward For RXC004
18th Jun 20187:15 amEQSHardman & Co Research: Redx Pharma (REDX): 'Focus, Realism and Results' - Ian Ross, Chairman
4th Jun 20187:00 amRNSDirectorate Update and Grant of Options
30th May 20187:00 amRNSInterim Results
15th May 201812:00 pmEQSHardman & Co Research: Redx Pharma (REDX): Clinical and corporate update
25th Apr 201810:57 amRNSShare Purchase by Chairman
25th Apr 20189:05 amRNSSecond Price Monitoring Extn
25th Apr 20189:00 amRNSPrice Monitoring Extension
24th Apr 20187:00 amRNSRedx Appoints Senior AstraZeneca Executive as CEO
13th Apr 20188:19 amRNSHolding(s) in Company
12th Apr 201811:28 amRNSHolding(s) in Company
29th Mar 20187:00 amRNSRXC004 Clinical Trial Update
22nd Mar 20187:00 amRNSRedx and Deinove sign option and licence agreement
15th Mar 20187:00 amRNSPoster Presentation at AACR Annual Meeting
6th Mar 20184:33 pmRNSResult of AGM
12th Feb 201810:23 amRNSPosting of Annual Accounts & AGM notice
6th Feb 20187:00 amRNSFirst Patient Dosed in Phase 1/2a Trial of RXC004
22nd Jan 20187:00 amRNSAppointment of Chief Medical Officer
28th Dec 201711:28 amRNSHolding(s) in Company
27th Dec 20175:45 pmRNSShare Purchase by Directors
22nd Dec 20177:00 amRNSGrant of Options
20th Dec 20177:00 amRNSFinal Results for the Year Ended 30 September 2017
14th Dec 20173:56 pmRNSHolding(s) in Company
8th Dec 20175:04 pmRNSHolding(s) in Company
14th Nov 201711:30 amRNSDirector/PDMR Shareholding
13th Nov 20177:15 amRNSHardman Research: Streamlined and clean
6th Nov 201712:00 pmRNSRestoration - Restoration Redx Pharma plc
6th Nov 20177:00 amRNSRedx updates strategy and resumes shares trading
27th Oct 20178:00 amRNSUpdate on Application to the High Court
13th Oct 20177:00 amRNSUpdate on Court Process
31st Aug 20179:00 amRNSRedx to present new scientific data at ESMO 2017
24th Aug 20179:42 amRNSDistribution to Unsecured Creditors
14th Aug 201710:05 amRNSDirectorate Change
10th Aug 20178:00 amRNSPublication of Joint Administrators' Proposals

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.